VOLIN and KJON-Two novel hyperdiploid myeloma cell lines.
Multiple myeloma can be divided into two distinct genetic subgroups: hyperdiploid (HRD) or nonhyperdiploid (NHRD) myeloma. Myeloma cell lines are important tools to study myeloma cell biology and are commonly used for preclinical screening and testing of new drugs. With few exceptions human myeloma cell lines are derived from NHRD patients, even though about half of the patients have HRD myeloma. Thus, there is a need for cell lines of HRD origin to enable more representative preclinical studies. Here, we present two novel myeloma cell lines, VOLIN and KJON. Both of them were derived from patients with HRD disease and shared the same genotype as their corresponding primary tumors. The cell lines' chromosomal content, genetic aberrations, gene expression, immunophenotype as well as some of their growth characteristics are described. Neither of the cell lines was found to harbor immunoglobulin heavy chain translocations. The VOLIN cell line was established from a bone marrow aspirate and KJON from peripheral blood. We propose that these unique cell lines may be used as tools to increase our understanding of myeloma cell biology. © 2016 Wiley Periodicals, Inc.
K.G. Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, NTNU-Norwegian University of Science and Technology, Trondheim, Norway.|Department of Pathology and Medical Genetics, St. Olav's University Hospital, Trondheim, Norway.
Thea Kristin
TK
Våtsveen
K.G. Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, NTNU-Norwegian University of Science and Technology, Trondheim, Norway.|Department of Immunology and Transfusion Medicine, St. Olav's University Hospital, Trondheim, Norway.
Magne
M
Børset
K.G. Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, NTNU-Norwegian University of Science and Technology, Trondheim, Norway.
Aida
A
Dikic
K.G. Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, NTNU-Norwegian University of Science and Technology, Trondheim, Norway.
Erming
E
Tian
Section for Cancer Cytogenetics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Francesca
F
Micci
Department of Core Facilities, Oslo University Hospital, Oslo, Norway.
Ana H B
AH
Lid
Department of Core Facilities, Oslo University Hospital, Oslo, Norway.|Department of Tumor Biology, Oslo University Hospital, Oslo, Norway.
Leonardo A
LA
Meza-Zepeda
Bioinformatics Core Facility, Department of Cancer Research and Molecular Medicine, Faculty of Medicine, NTNU - Norwegian University of Science and Technology, Trondheim, Norway.
Eivind
E
Coward
K.G. Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, NTNU-Norwegian University of Science and Technology, Trondheim, Norway.|Department of Hematology, St. Olav's University Hospital, Trondheim, Norway.
Anders
A
Waage
K.G. Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, NTNU-Norwegian University of Science and Technology, Trondheim, Norway.|Centre of Molecular Inflammation Research, NTNU-Norwegian University of Science and Technology, Trondheim, Norway.
Anders
A
Sundan
Genetics Branch, National Cancer Institute, Bethesda, MD.
W Michael
WM
Kuehl
K.G. Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, NTNU-Norwegian University of Science and Technology, Trondheim, Norway. toril.holien@ntnu.no.
Toril
T
Holien
D000782:Aneuploidy; D045744:Cell Line, Tumor; D004171:Diploidy; D006801:Humans; D016130:Immunophenotyping; D009101:Multiple Myeloma / Q000235:genetics / Q000473:pathology*; D014178:Translocation, Genetic